DPP4 and Hyperglycemia: Due to their good safety profile, essentially devoid of side effects, DPP4 inhibitors are suitable pharmacological agents for post-bariatric patients with mild hyperglycemia; however, they would not be appropriate as monotherapy for significant hyperglycemia or to induce weight loss due to only modest improvement in A1c (0.7%) and no impact on weight.